Patrick C. Johnson, Md

This study tests whether adding the drug acalabrutinib to a CAR-T cell therapy (lisocabtagene maraleucel) can improve outcomes for people with aggressive B-cell lymphoma that has returned or not responded to prior treatment. About 28 adults will receive the combination, and resea…